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Abstract: OBJECTIVE: The burn victim’s inherent state of hyperinflammation frequently camouflages
septic events delaying the initiation of targeted intensive care therapy. Accurate biomarkers are ur-
gently needed to support sepsis detection before patients’ clinical deterioration. SUMMARY OF BACK-
GROUND DATA: Evidence on the usefulness of pancreatic stone protein (PSP) as a powerful diagnos-
tic and prognostic marker in critically ill patients has recently accumulated. METHODS: Analysis of
biomarker kinetics (PSP, routine markers) was performed on 90 patients admitted to the Zurich Burn
Center between May 2015 and October 2018 with burns ฀15% total body surface area with regard to
infection and sepsis (Sepsis-3) over a 14-day time course. RESULTS: PSP differentiated between sepsis,
infection and sterile inflammation from day 3 onward with an area under the curve of up to 0.89 (P <
0.001), therefore, competing with procalcitonin (area under the curve = 0.86, P < 0.001). Compared
to routine inflammatory biomarkers, only PSP demonstrated a significant interaction between time and
presence of sepsis - signifying a steeper increase in PSP levels in septic patients as opposed to those
exhibiting a nonseptic course (interaction P < 0.001). Event-related analysis demonstrated tripled PSP
serum levels within 72 hours and doubled levels within 48 hours before a clinically apparent sepsis. CON-
CLUSION: PSP is able to differentiate between septic and nonseptic patients during acute burn care. Its
steep rise up to 72 hours before clinically overt deterioration has the potential for physicians to timely
initiate treatment with reduced mortality and costs.
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Objective: The burn victim’s inherent state of hyperinflammation frequently
camouflages septic events delaying the initiation of targeted intensive care
therapy. Accurate biomarkers are urgently needed to support sepsis detection
before patients’ clinical deterioration.
Summary of Background Data: Evidence on the usefulness of pancreatic
stone protein (PSP) as a powerful diagnostic and prognostic marker in
critically ill patients has recently accumulated.
Methods: Analysis of biomarker kinetics (PSP, routine markers) was per-
formed on 90 patients admitted to the Zurich Burn Center between May 2015
and October 2018 with burns 15% total body surface area with regard to
infection and sepsis (Sepsis-3) over a 14-day time course.
Results: PSP differentiated between sepsis, infection and sterile inflamma-
tion from day 3 onward with an area under the curve of up to 0.89 (P< 0.001),
therefore, competing with procalcitonin (area under the curve ¼ 0.86, P <
0.001). Compared to routine inflammatory biomarkers, only PSP demon-
strated a significant interaction between time and presence of sepsis –
signifying a steeper increase in PSP levels in septic patients as opposed to
those exhibiting a nonseptic course (interaction P < 0.001). Event-related
analysis demonstrated tripled PSP serum levels within 72 hours and doubled
levels within 48 hours before a clinically apparent sepsis.
Conclusion: PSP is able to differentiate between septic and nonseptic
patients during acute burn care. Its steep rise up to 72 hours before clinically
overt deterioration has the potential for physicians to timely initiate treatment
with reduced mortality and costs.
Keywords: biomarker analysis, kinetics of biomarkers, pancreatic stone
protein, PSP, sepsis biomarker
(Ann Surg 2020;xx:xxx–xxx)
A lthough the overall survival of extensive burns has increasedover time due to sophisticated burn wound care, radical infection
control measures, altered fluid resuscitation protocols and enhanced
nutritional support, mortality remains substantial with up to 50% and
is, therefore, higher than that associated with heart failure or most
cancer rates.1–7 The incidence of septic courses secondary to thermal
injuries varies in literature between 3% and 30% for cases with burns
covering over 15% total body surface area (TBSA).4,8
A major limiting factor for the poor clinical outcome of septic
patients – even under best possible care – is the lack of reliable
diagnostic tools with the prompt recognition of critical events.9 This
is even more challenging in burns, as thermal injuries lead to a
state of hyperinflammation, capillary leakage and hypermetabolism
triggering dysfunctional catabolic circuits in nearly every organ
system.4,10,11 Clinical signs expressing the enormous stress caused
by the thermal injury itself such as fever, hypothermia, tachycardia,
or hyperventilation frequently mask infectious events and, therefore,
make the delineation between sterile inflammatory processes and
infectious/septic progressions significantly challenging. Conse-
quently, physicians depend on blood biomarkers to help uncover
infectious events at an incipient stage of the disease. Though,
established inflammatory biomarkers such as white blood cells
(WBCs), C-reactive protein (CRP), procalcitonin (PCT), or interleu-
kin-6 often fail in that respect – especially in burn patients – for
different reasons.12–15 Likewise, novel promising biomarkers
derived from the omics or inflammasome families are currently
being investigated, but for now lack broader evidence, availability,
and affordability.16–18
Evidence on the usefulness of the pancreatic stone protein
(PSP) as an accurate diagnostic and prognostic marker in critically ill
patients has recently been increasing.19 Originally described as a
protein constitutively secreted by pancreatic acinar cells to inhibit
growth and nucleation of calcium carbonate crystals, insights from
more recent studies suggested PSP as an acute phase protein activat-
ing neutrophil granulocytes in the early phase of infection leading to
an appreciation of a much broader functional scope. Serum PSP
levels were found to be highly predictive for infectious and septic
courses of neonates, trauma patients, cardiac surgery patients, emer-
gency patients as well in a broad range of intensive care unit (ICU)
patients with areas under the curve (AUC) of up to 0.91, thus being
able to compete with well-established biomarkers like PCT.20–25
Reding and colleagues have further emphasized the role of the
pancreas as an acute phase organ by sensing remote tissue damage,
therefore, triggering the release of PSP, particularly when associated
with septic complications.26,27
Especially in burn patients, where early decision making with
initiation of therapy is key to survival, inflammatory biomarkers are
urgently needed aiming at the preclinical detection of deterioration to
sepsis or septic shock. Serum levels of circulating PSP and their
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predictive usefulness for infection and sepsis have not yet been
studied in this critically ill population so far. In this study, we
analyzed the first 14 days of serum PSP in a cohort of 90 severely
burned patients (15% TBSA) to determine its discriminatory
accuracy to delineate sterile systemic inflammation from infec-
tious/septic courses as compared to currently available inflammatory
biomarkers (WBCs, CRP, PCT). We particularly focused on the






Approval was obtained from the Ethics committee of the
University of Zurich, Switzerland on April 20th 2015 (KEK-ZH-
No: 2014-0631).
Sample Size
We focused on the interaction between time (14 time points)
and status of sepsis (ie, 2 groups) as the most relevant hypothesis,
because bedside clinicians are interested in the change over time of a
biomarker to detect a patient’s deterioration. Previous findings on
PSP in infected patients performed by our group revealed an effect
size Cohen f¼ 0.2 (0.10, 0.25, and 0.40 represent small, medium, and
large effect sizes, respectively).21 Due to the burn patients inherent
baseline inflammation potentially interfering with biomarker levels
in infected/septic patients, we chose an even lower, conservative
effect size of about 0.1–0.15 for the present study. Based on the
these pre-study considerations, a priori sample size estimation
was performed using GPOWER 3.1 resulting in 82 patients
required (given a ¼ 0.05, power ¼ 0.9, effect size ¼ 0.1, number
of measurements ¼ 14, correlation among measurements ¼ 0.5).28
Participants
Between May 2015 and October 2018, patients with burns
15% TBSA admitted to our burn center were asked for participa-
tion. Affected TBSAwas determined using Lund Browder charts. A
minimum TBSA of 15% was set for inclusion based on evidence of
systemic stress, impaired immunity, and massive fluid shifts.8,29
Exclusion criteria were age <18 years, current infection at admis-
sion, immunosuppressive medication, and burn injuries older than
6 hours. All patients received comprehensive oral and written infor-
mation on the present study and had to sign the informed consent for
enrollment. Close relatives and authorized representatives were
asked for informed consent by proxy, if the patient was unable to
consent due to the extent of the injury.
Measurement of Serum/Plasma Biomarker
Concentration
Blood samples were drawn daily at 6 AM, starting at admission
to our burn center, for measurement of conventional inflammatory
biomarkers (CRP,WBCs, and PCT) and PSP. Leukocyte counts, CRP
and PCT levels were directly measured by routine testing at the
Institute of Clinical Chemistry, University Hospital Zurich. For
subsequent analysis, serum samples were stored at 808C. The
concentration of PSP/REG Iawas measured with an isoform specific
enzyme-linked immunosorbent assay, which was established in our
laboratory.30,31Antibodies (affinity-purified IgG) made in guinea pig
anti-PSP/REG Ia were diluted 1:500 in Tris-buffered saline (TBS:
10mM Tris; 0.9% NaCl) and coated on 96-well Maxisorp Nunc
plates at room temperature over night or at 48C if incubation lasted
longer than 1 night. Nonadherent antibodies were removed with 3
washing steps. The wash buffer consisted of TBS and 0.05% Tween.
Bovine serum albumin (BSA, tested for low level PSP/REG Ia
content) 1% in TBS was used to block the plates for at least 1 hour
at room temperature. Serum samples collected from patients were
pre-diluted in 1% BSA/TBS and loaded on the plate in duplicates.
The standard curve was generated by a dilution series ranging from 4
ng/mL and 0.1 ng/mL, prepared with recombinant PSP. In addition, a
blank was added. After 1 hour of incubation and 3 washing steps a
secondary antibody, rabbit anti-PSP/REG Ia, 1:500 diluted in 1%
BSA/TBS was incubated in the plate. Subsequently, a biotinylated
phosphatase antibody 1:6000 diluted in 1% BSATBS was added for
1 hour. After another washing step, the phosphatase substrate
(SIGMA Aldrich, Buchs, Switzerland) was added, which was previ-
ously dissolved in alkaline phosphatase buffer according to instruc-
tions. PSP was detected photometrically at 405 nm.
Patient-related Data
Besides demographic data [age, sex, body mass index (BMI),
comorbidities] and trauma-related data (TBSA, mechanism of injury,
inhalation injury), clinical parameters were extracted from the
patients’ chart retrospectively and collected in the case report form
for 14 consecutive days after admission. The latter included: blood
count, electrolytes, inflammatory markers (PCT, CRP), liver, kidney,
and pancreas function. The abbreviated burn severity index (ABSI)
score was used as prognostic stratification system including age, sex,
TBSA, third degree burns, and inhalation injury.32Additionally, vital
signs and data on circulatory support, ventilation, and mental status
were collected to closely study pathophysiological changes with
regard to infection and sepsis. Clinical parameters at the timepoint of
blood sampling were chosen for analysis (usually at 6 AM daily). All
treating physicians were blinded to PSP results whereas they were
aware of WBCs, CRP, and PCT values. We used the Centers for
Disease Control and Prevention-definition for hospital acquired
infections and the Third International Consensus Definition for
Sepsis and Septic Shock (Sepsis-3).33,34 The corresponding time
point of any infection or sepsis was determined by the date of
sampling, which subsequently turned out positive.
Statistical Analysis
Discrete values are expressed as counts with percentages,
whereas continuous variables are presented as mean  standard
deviation or median with interquartile range (IQR) as appropriate.
Baseline characteristics were compared between groups using Chi-
square test for counts and univariate analysis of variance for contin-
uous data. Pearson product-moment correlation was performed to
identify associations between levels of biomarkers at admission and
continuous baseline characteristics. Biomarker time courses were
compared between groups using a linear mixed effects regression
model with random intercepts. Linear mixed models have proven
superior to traditional repeated-measures analysis of variance as they
properly take into account interindividual differences in complex
longitudinal data.35 Univariate binary logistic regression analysis
was used to test PSP, PCT, CRP, and WBC as predictors for the
clinical outcome. Receiver operating characteristics analysis was
employed at each day to evaluate the diagnostic/prognostic perfor-
mance of the biomarkers tested with regard to infection and sepsis.
Values of the AUC are reported with corresponding 95%-confidence
interval. Cut-off points for PSP levels were selected giving equal
weight to sensitivity and specificity. All tests were 2 tailed; P < 0.05
was considered significant. Data were analyzed using SPSS (Statis-
tical Package for Social Sciences, Version 24 for Macintosh; SPSS
Inc., Chicago, IL) and GraphPad Prism version 6.00 for Macintosh
(GraphPad Software, La Jolla CA).
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RESULTS
Baseline Characteristics of Study Population
Baseline characteristics of the study population in total and
according to the main outcome (no infection vs infection vs sepsis vs
septic shock) are given in Table 1. Ninety severely burned patients
(18 female) with TBSA 15% were included. We pooled the septic
and septic shock group for further analyses due to the low number of
patients with septic shock (n¼ 7). Thirteen patients (14%) exhibited
a local infection, whereas 46 patients (51%) developed septic
complications within the first 14 days. Mean age was 48.5 18.8
years and did not differ between the 3 groups (P ¼ 0.595). Total
median TBSAwas 31.5% (IQR 21%) and differed significantly in the
subgroup analysis [no infection: 29% (IQR 24%), local infection:
25% (IQR 18%), sepsis: 35% (IQR 26%); P ¼ 0.048]. Fourteen
patients (16%) died. Septic/infected patients had a comprehensibly
longer stay in the ICU and longer total length of stay in the hospital
than patients with an uneventful course (P < 0.001). We focused on
the first infectious event that occurred within the first 14 days
observing pneumonia in 34 patients (58%), followed by wound
infections in 12 patients (20%), 6 patients with central line infection
(10%), bacteremia in 4 patients (7%), and 3 patients (5%) with
urinary tract infection (Table 1).
Association Between Inflammatory Markers and
Baseline Characteristics
Age and BMI did not correlate with PSP, WBCs, and PCT at
baseline (P > 0.100), whereas CRP at baseline showed a mild
association with age (r ¼ 0.26, P ¼ 0.021) and BMI (r¼ .28,
P ¼ 0.019). TBSA did not correlate with levels of PSP, PCT, and
CRP at baseline, but was moderately associated with WBCs at
baseline (r¼ .55, P< 0.001). A linear mixed effect regression model
investigating the influence of TBSA over 14 days showed a signifi-
cant interaction between time and TBSA for all biomarkers, which is
why all subsequent analyses were adjusted for TBSA (interaction for
all biomarkers P < 0.001). In an equal model, age had a significant
effect on the time course of PSP (interaction P ¼ 0.014). However,
when adjusting the latter model for TBSA, age lost its significant
effect (interaction P ¼ 0.390). All biomarker levels were unaffected
by sex and the presence of diabetes mellitus (P> 0.100). The 14-day
time course of all biomarkers according to the median split for age
(52 years) and TBSA (31.5%) is given as supplemental material
(Supplemental 1, http://links.lww.com/SLA/B969 and 2, http://links.
lww.com/SLA/B969). Additionally, PSP levels of 32 patients drawn
at a later time point (at least 3 months after discharge from hospital)
did not differ from PSP at admission in paired samples t-test (P ¼
0.094) underlining the validity of the baseline values as not being
influenced by trauma severity.
Time Course of Inflammatory Biomarkers as
Related to Infection and Sepsis
To delineate sterile inflammation from infection and sepsis,
we focused on the first 10 days after trauma encompassing >90% of
the outcome events and adjusted the model for TBSA. Using linear
mixed effect regression analysis, PSP was able to differentiate
between infection, sepsis and sterile inflammation from day 3 ongo-
ing, whereas PCT distinguished between the 3 groups at every time
point. CRP was able to differentiate between noninfection, infection,
TABLE 1. Baseline Characteristics in Total and According to the Main Outcome No Infection Versus Infection Versus Sepsis
Versus Septic Shock. For Group Comparison, Sepsis and Septic Shock Patients Were Clustered. Counts Were Compared Row-
wise Using Chi-square Test, Continuous Variables Were Tested With Univariate ANOVA After Log10-Transformation Where
Appropriate
Total No Infection Local Infection Sepsis Septic Shock P
Number of patients 90 31 (34.4%) 13 (14.4%) 39 (43.3%) 7 (7.8%) —
Sex (n, %)
Female 18 (20%) 6 (33.3%) 3 (16.7%) 7 (38.9%) 2 (11.2%) 0.956
Male 72 (80%) 25 (34.7%) 10 (13.9%) 32 (44.4%) 5 (6.9%)
Age (yr; mean  SD) 48.5 18.8 51.3 20.4 46.6 17.6 47.6 18.1 44.1 20.6 0.595
TBSA (%; median (IQR)) 31.5 (21) 29 (24) 25 (18) 34 (15) 48 (28) 0.048
BMI (kg/m2; meanSD) 27.3 6.1 29.4 7.7 25.7 4.1 26.4 5.2 26.1 4.2 0.057
Trauma mechanism (n, %)
Burn 72 (80.0%) 24 (33.3%) 10 (13.9%) 32 (44.4%) 6 (8.3%) 0.149
Scald 14 (15.6%) 7 (50.0%) 3 (21.4%) 3 (21.4%) 1 (7.1%)
Electrical 4 (4.4%) 0 0 4 (100%) 0
Inhalation injury (n, %) 25 (27.8%) 7 (28.0%) 2 (8%) 11 (44.0%) 5 (20%) 0.281
Diabetes mellitus (n, %) 4 (4.4%) 0 0 3 (75%) 1 (25%) 0.135
Total length of stay (d; median (IQR)) 28 (40) 16 (24) 30 (35) 51 (61) 24 (93) <0.001
ICU length of stay (d; median (IQR)) 16 (32) 5 (13) 21 (18) 29 (40) 17 (72) <0.001
ABSI (median (IQR)) 7.5 (4) 7 (6) 7 (2) 8 (2) 11 (5) 0.113
Baux score (median (IQR)) 84 (38) 84 (49) 73.5 (39) 84 (33) 104.5 (29) 0.307
Mortality (n, %) 14 (15.6%) 10 (71.4%) 0 2 (14.3%) 2 (14.3%) 0.005
Type of infection (n, %)
Wound infection 12 (20.3%) — 3 (25%) 8 (66.7%) 1 (8.3%) —
Pneumonia 34 (57.6%) — 4 (11.8%) 26 (76.5%) 4 (11.8%) —
Urinary tract infection 3 (5.1%) — 3 (100%) 0 0 —
Central line infection 6 (10.2%) — 2 (33.3%) 4 (66.7%) 0 –
Bacteremia 4 (6.8%) — 1 (25%) 1 (25%) 2 (50%) –
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and sepsis at day 2, 7, 8, and 10, and WBCs merely at admission. Of
note, only PSP demonstrated a significant interaction between time
and presence of sepsis – signifying a significantly steeper increase in
PSP levels in septic patients as opposed to those exhibiting a non-
septic course (interaction PPSP < 0.001, PPCT ¼ 0.135, PWBCs ¼
0.166, PCRP ¼ 0.118) (Fig. 1).
To further corroborate the predictive ability of PSPwith regard
to the status of sepsis, we employed univariate binary logistic
regression with receiver operating characteristic curve (ROC) curve
analysis. PSP was able to predict septic courses from day 3 to day 10
after trauma with an AUC of up to 0.89 at day 7 (P < 0.001), thus
competing with the predictive ability of PCT achieving a maximum
AUC of 0.86 (P < 0.001) at day 8. Combination of PSP and PCT
demonstrated even higher AUCs ranging between 0.90 and 0.92 at
day 6–10 (Fig. 2). Only day 3 after trauma demonstrated a remark-
able increase by 11% when combining the 2 markers. Combining
PSP and ABSI score in the binary logistic regression model yielded
no remarkable increase of accuracy (S3). CRP and WBCs showed
less predictive ability with AUC below 0.8. Giving equal weight to
both sensitivity and specificity, we selected 60.12 ng/mL for PSP as
FIGURE 1. Main effects analysis determined that PSP differentiated between infection, sepsis, and sterile inflammation from day 3
ongoing, whereas PCT distinguished between the 3 groups at every time point. CRPwas able to differentiate between noninfection,
infection, and sepsis at day 2, 7, 8, and 10, and WBCs at admission only. PSP demonstrated a significant interaction between time
and presence of sepsis – signifying a significantly steeper increase in PSP levels in septic patients as opposed to those exhibiting a
nonseptic course (interaction PPSP < 0.001, PPCT ¼ 0.135, PWBCs ¼ 0.166, PCRP ¼ 0.118). CRP indicates C-reactive protein; PCT,
procalcitonin; PSP, pancreatic stone protein; WBCs, white blood cells.
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cut-off value being able to predict yet clinically unapparent septic
courses at day 7 after trauma (sensitivity/specificity: 81%, positive
likelihood ratio: 4.34). PSP demonstrated no predictive power for
local infections without septic complications (AUC  0.60, P >
0.20), whereas PCT was able to predict local infections with AUC
ranging between 0.70 and 0.80 (P < 0.05).
Event-related Analysis of Inflammatory Biomarkers
To further elucidate the interaction between time and status of
disease (infection, sepsis, septic shock), we rearranged the individual
biomarker courses according to their time point of occurrence and
used the grand median of patients with an uneventful course as
reference line. This event-related analysis demonstrated PSP serum
levels to triple within 72 hours and to double within 48 hours before a
clinically apparent sepsis with subsequent initiation of therapy.
Likewise, PSP levels appeared 10-fold higher within 48 hours before
septic shock was clinically overt. In contrast, PSP serum values
hardly varied in patients with a local infection before the event
(Fig. 3). PCT serum levels nearly tripled in patients with septic shock
and doubled in patients with local infections within 72 hours before
the event, whereas septic patients demonstrated merely marginal
alterations. CRP serum levels showed an circa 1.5-fold increase in
patients with local infections and septic complications within
72 hours before clinically overt. In the same time frame, CRP
doubled in patients with septic shock. Eventually, serum levels of
WBCs demonstrated unspecific undulations within 72 hours before
diagnosis of the corresponding event.
DISCUSSION
The present study investigated the time course of PSP and 3
established pro-inflammatory biomarkers (PCT, CRP, WBC) in a
cohort of 90 severely burned patients with regard to the incidence of
infection and septic complications within the initial 14 days after
trauma resulting in >1000 measurements per biomarker. Moreover,
PSP was the only biomarker demonstrating a significant interaction
between time and presence of sepsis – indicated by a significantly
steeper increase in PSP levels in septic patients as opposed to those
without sepsis. This interaction suggests that – besides a cut-off
value – the time-related kinetics of PSP has a crucial role in the
preclinical identification of septic patients. Interestingly, patients
with a local infection demonstrated nearly the same values as those
with no infection, suggesting for PSP to have a critical role in the
sepsis pathway compared to inflammatory cascades reigning local
infections or wound related inflammation. This finding reflects the
high specificity of PSP with regard to septic courses and confirms the
results of previous studies.20,25
Day-wise main effect analysis showed that PCT was able to
differentiate between no infection, infection, and sepsis at all of the
time points, whereas PSP demonstrated discriminatory power from
day 3. On the one hand, the high performance of PCT underlines the
validity of our study results because several previous studies have
demonstrated PCT to be raised in burned patients with infectious and
septic courses.36–38On the other hand, it is unlikely that an increased
level of PCT at admission really signifies a yet clinically unapparent
infection. In that way, PSP demonstrated a more comprehensible
course with indifferent levels during the first 2 days followed by a
significant increase 3 days after trauma. Corresponding binary
logistic regression with ROC-curve analysis replicated the day-wise
main effect analysis of the linear mixed model with PSP and PCT
being highly predictive for septic events.
When combining PSP and PCT, the ROC-curve analysis
achieved even higher AUCs ranging between 0.90 and 0.92 at
day 6–10. On the one hand, the increase of accuracy is favorable,
on the other hand, it is limited to 2%–3%. Only day 3 after trauma
demonstrated a remarkable increase by 11% when combining the 2
markers. Moreover, adding the ABSI score to PSP in the binary
logistic regression model yielded marginally higher AUC values at
single days. One reason for this observation could be, that the ABSI
score is a static score that is evaluated once and does not change over
time, and, therefore, may not necessarily reflect the dynamic
changes that lead to sepsis development. These data suggest, that
combining PSP and PCT might be advantageous especially in the
early phase after trauma, whereas the ABSI score has no further gain
in sepsis identification. But it is to be noted, that standard ROC curve
analysis represents a theoretical model, which does not account for
time dependency of an event. This limitation of considering an event
(ie, sepsis) status for an individual as fixed over time is often
encountered in biomarker studies and demands cautious data inter-
pretation. Therefore, the event-related analysis as shown in Fig. 3
compensates for that and reflects the predictive strength of a
biomarker better. Against this background, PSP alone has excellent
predictive ability towards septic progression, which can hardly be
amplified by adding further powerful markers, such as PCT. In the
authors’ view and as demonstrated in previous studies, PCT rather
has its strength in guiding antibiotic therapy than in predicting
sepsis.13
FIGURE 2. Left: Binary ROC-curve analysis with AUC and 95%-CI demonstrating PSP to predict septic courses from day 3 to day 10
after traumawith AUC of up to 0.89 at day 7.Middle: PCTshowed predictive ability from admission with amaximumAUC of 0.86 at
day 7. CRP andWBCs (not shown) demonstrated less predictive ability with AUC below 0.8. Right: ROC curve of combined PSP and
PCT demonstrating AUCs ranging between 0.90 and 0.92. AUC indicates area under the curve; CRP, C-reactive protein; PCT,
procalcitonin; PSP, pancreatic stone protein; ROC, receiver operating characteristic curve; WBCs, white blood cells.
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FIGURE 3. Event-related depiction of PSP and routine inflammatory biomarkers. PSP serum levels tripled within 72h and doubled
within 48h before a clinically apparent sepsis. In septic shock, PSP levels appeared 10-fold higher within 48h before clinically overt.
PCT serum levels nearly tripled in patients with septic shock and doubled in patients with local infections within 72h before the
event, whereas septic patients demonstrated merely marginal alterations. CRP and WBC serum levels demonstrated unspecific
undulations within 72h before diagnosis of the corresponding event. The boxes in orange and red contain the relative biomarker
increase for sepsis and septic shock for 72h, 48h, and 24h, respectively. Note the log-transformed ordinate with different scales.
CRP, C-reactive protein; PCT, procalcitonin; PSP, pancreatic stone protein; WBCs, white blood cells.
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The ultimate goal in sepsis biomarker research, however, is the
development of a score that is useful for sepsis diagnosis and risk
stratification. With the availability of systems biology approaches,
such a sepsis score may ideally comprise a combination of several
biomarkers, including proteomic, transcriptomic, and metabolomic
candidates as wells as clinical parameters. Examples of preliminary
scores in different sepsis cohorts include the combination of clinical
and transcriptomic markers,39,40 metabolic and protein-mediator
profiling,41 or the combination of biomarkers with established
clinical scores.42 In our opinion, PSP is a very promising candidate
to be included in a sepsis score in general and in particular for
discrimination of septic complications in patients with underlying
systemic inflammation as indicated by the results of the present
study. Still, based on the experience of previous studies, the devel-
opment of a multi-biomarker score for predicting and diagnosing
sepsis represents an intricate endeavor.43 The implementation of
novel fields, such as bioinformatics, computational biology, and
machine learning, into sepsis research might open up new possibili-
ties to adequately reflect the complexity and dynamics of sepsis for
development of a valid and reliable diagnostic tool in the future. Even
if the development of a sepsis score is beyond the scope of the present
manuscript, current and future efforts by our research group head
towards this direction.
We identified 45.67 ng/mL as cut-off value to predict clini-
cally unapparent sepsis at day 3 after trauma, which closely corre-
sponds with the cut-off level of 48.1 ng/mL for cardiac surgery
patients in a previous report.21Nevertheless, these results have to be
interpreted with caution as the time-dependency of the infectious/
septic event is not included in standard ROC curve analysis. The
limitation of considering an event (disease) status for an individual
as fixed over time is often encountered in biomarker studies, harshly
restricting the external validity of the results. Therefore, we rear-
ranged the individual course with regard to the time point of the
event to account for time-dependency. In this event-related analysis,
PSP outperformed the canonical biomarkers by its relative increase
even 72 hours before clinical diagnosis of sepsis. Despite the small
number of patients with septic shock, we realized the relevance of a
steep slope of PSP before becoming clinically apparent. Even PCT
did neither increase earlier in relation to the event norwas its relative
rise as steep as the corresponding PSP levels. The importance of the
time profile of a biomarker might even bemore helpful to physicians
than a cut-off value per se and has been discussed for burn patients
before.44 Accordingly, these considerations suggest that PSP kinet-
ics help identify patients with evolving sepsis. This may result in
early microbiological sampling, initiation of preemptive antibiotic
therapy and prevention of fatal sepsis development with
reduced costs.
Baseline PSP levels were not correlated with the relevant
patient- and trauma-related characteristics (sex, age, BMI, TBSA),
which is desirable for a sepsis biomarker demanding high specificity.
However, the employed mixed model analysis demonstrated a
significant interaction between time and TBSA over 14 days for
PSP, PCT, and CRP, which is why we adjusted all subsequent
analyses for TBSA. Trauma severity seems to have an influence
on the serum levels of PSP (and other pro-inflammatory biomarkers),
which has been described before.20,21 But as our further analysis
revealed, TBSA as surrogate parameter for trauma severity most
likely functions as moderator variable because patients with higher
TBSA are more susceptible to septic events expressed by higher
biomarker levels than those with less TBSA.
The molecular mechanism by which PSP reacts to infection is
still unclear. Graf et al and Reding et al showed that the pancreas
as the main locus of synthesis senses remote organ damage and
systemic stress via cytokine storms and responds by secreting PSP,
particularly when associated with septic complications.26,31 Hence,
the pancreas is also considered an acute phase organ. Once released
in the bloodstream, PSP plays a role in activating neutrophils.20 Of
note, PSP has been demonstrated to bear a high degree of structural
homology with lectins, which are calcium-dependent glycan-binding
proteins known to have a diverse range of functions, including
adhesion and signaling receptors in homeostasis and innate immu-
nity, and are crucial in the inflammatory response and leukocyte and
platelet trafficking.19
As early decision making with the initiation of therapy is
key to survival, especially in burns, inflammatory biomarkers are
urgently needed aiming at preclinical detection of deterioration.
Vice versa, this patient population has some major methodological
advantages when it comes to testing novel biomarkers as compared
to other ICU patients making up for some key limitations of
previous studies: (A) Prophylactic administration of antibiotics,
which is generally considered a major incommoding confounder in
sepsis-related biomarker research, is strongly avoided in thermally
injured patients due to resistance breeding.20,21 (B) The burn
victim itself is mostly young to middle-aged with no or few
comorbidities thus harshly diminishing confounding effects. (C)
ICU stay of burn victims is usually prolonged. Therefore, detailed
monitoring and documentation of clinical and laboratory param-
eters are valuable prerequisites to retrospectively identify rapid
changes in patient’s condition. (D) Burn victims are thought to be
more susceptible to infectious complications than any other patient
population allowing for statistically balanced juxtaposition of
septic versus nonseptic patients.45 (E) Except for the minor
subgroup of high voltage injuries, burns represent a rather homog-
enous entity with directly measurable trauma severity (ie, TBSA,
degree of burn injury), which can be simply adjusted for in
statistical analyses.
Elucidating the role of PSP in severely burned patients with
respect to the occurrence of sepsis, the present study represents a
crucial step on the way to test a potentially helpful biomarker for
early sepsis detection. Besides its high predictive power and its early
temporal increase, PSP can readily be measured bedside from a drop
of whole blood using a nanofluid based assay (abioSCOPE, Abionic
SA, Epalinges, Switzerland). This device allows quantifying PSP
levels at a picomolar range within 2–5 minutes and without pre-
analytical work. In this context, the present study needs to be
considered as hypothesis generating awaiting confirmation in future
clinical trials, since yet, there are some limitations: Given the single-
center design of our study, there is no external validation of our data,
which has to be addressed in further studies. Likewise, measurement
of biomarkers and assessment of clinical parameters were performed
only once per 24 hours, neglecting potential alterations between these
intervals. Moreover, the influence of the type of infection and of
repetitive surgical tissue damage on PSP serum levels need to be
clarified in further studies.
CONCLUSIONS
PSP demonstrates high discriminatory ability to timely identify
evolving sepsis and septic shock in patientswith acute severe burns. Its
steep increase allows sepsis detection up to 72hours before clinically
overt deterioration, thus outperformingCRP- andPCT-based protocols
for sepsis diagnosis. Affordable PSP bedside measurement might
enable earlier treatment of sepsis with reduced morbidity, mortality
and reduce costs for burn patients in the future.
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